Wednesday 12 August 2026

One To Watch

Tr1X

A privately-held biotech focused on engineering cures for immune and inflammatory diseases.

Company Overview

Want to Update your Company's Profile?


Latest Tr1X News

Tr1X sets off on Treg and CAR-Treg mission with $75 million
18 January 2024
More Tr1X news >


Today's issue

Tenax Thera tanks on Phase III trial miss for TNX-103 in PH-HFpEF
Pharmaceutical
Tenax Thera tanks on Phase III trial miss for TNX-103 in PH-HFpEF
11 August 2026
Biotechnology
CellProthera inks MoU for ProtheraCytes distribution in Japan
11 August 2026
Pharmaceutical
Obesity focused Kailera appoints Nur Nicholson as CTO
11 August 2026
Pharmaceutical
Long-acting therapies continue to gain momentum in HIV
11 August 2026
Pharmaceutical
FDA rejects ITM’s ¹⁷⁷Lu-edotreotide filing
11 August 2026
Pharmaceutical
Pharma as its own retailer
11 August 2026
Biotechnology
Silence Therapeutics' siRNA hits the mark in polycythemia vera
11 August 2026




Copyright © The Pharma Letter 2026

 |  Headless Content Management with Blaze